Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The anti-miR-663 vector is a research tool designed to inhibit the activity of microRNA-663 (miR-663). miR-663 plays a role in mitochondria-to-nucleus retrograde signaling and epigenetically regulates the expression of nuclear-encoded respiratory chain subunits and assembly factors, including NDUFAF1, SDHAF2, UQCC2, and SCO1, with direct regulation of UQCC2. Inhibition of miR-663 by this vector has been shown to reduce OXPHOS complex activity, increase cellular proliferation in vitro, and promote tumor development in vivo in mice. This suggests that miR-663 normally acts to suppress tumor progression. The vector is used to study the role of miR-663 in biological processes such as breast tumorigenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-miR-663 vector.